Bispecific antibody to target IgE-producing B cells for allergy treatment
Official title: Bispecific antibody targeting IgE-producing B cells for treating allergic diseases
Funded at Cellergy Pharma · NIH-11267229 · Data updated 2026-11-12
A new antibody therapy aims to selectively kill IgE-producing B cells to help people with severe allergic diseases feel better and reduce allergy symptoms.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellergy Pharma NIH-funded |
| Lab location | 1 site (Wilmington, UNITED STATES) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $294,407 |
| NIH project number | 5R41AI188995-02 |
| Project ID | NIH-11267229 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with severe allergic diseases where IgE-mediated responses drive symptoms; data from preclinical models will guide future human studies.
✕Less likely to help
People whose allergic disease does not involve IgE-mediated pathways or who are not suitable for antibody therapies may not benefit.
What this research studies
This project tests a novel antibody designed to specifically shut down the cells that make IgE, the thing that drives many allergic reactions. It will be studied in immunocompromised mouse models to see how potent and safe the drug is before considering human trials. The work focuses on whether the therapy can provide durable suppression of allergy symptoms with fewer side effects than current treatments. If successful, it could form the basis for future studies in people with asthma, food allergies, or chronic hives who struggle with severe symptoms.
Why it matters
Potential benefit: If successful, patients with severe allergies could experience fewer symptoms and a better quality of life through a therapy that targets the source of IgE.
How similar studies have gone: Previous approaches targeting IgE have shown promise, but complete suppression and durable benefit remain unmet goals, making this approach novel.
Where this research is happening
-
Cellergy Pharma
Wilmington, United States Active
Researchers
- Principal investigator: Ma, Zhengyu — Cellergy Pharma
- Study coordinator: Ma, Zhengyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.